Movement Alert｜Innovent Biologics Falls 3.15% in Regular Trading, Pfizer Deal Regulatory Uncertainty Compounds Biotech Sector Selloff

Market Focus06-02

On June 2, Innovent Biologics fell 3.15% in regular trading to HK$77.35 per share, with trading volume of HK$174 million. The decline marks the second consecutive session of pullback following the stock's 11%-plus surge on May 29 when the company announced a landmark $10.5 billion global strategic collaboration with Pfizer.

The Pfizer deal covers 12 early-stage oncology programs, with Innovent receiving $650 million upfront and up to $9.85 billion in milestone payments. Notably, Innovent's disclosure that the transaction requires regulatory approval has sparked market concern, particularly amid ongoing speculation about potential tightening of biomedical technology out-licensing (BD) regulations under the COINS Act framework.

The broader biotech sector experienced significant selling pressure, with Akeso down 6.21%, 3SBio down 8.32%, BeiGene down 3.56%, SKB Bio down 7.72%, and Remegen down 5.04%, creating systemic drag on Innovent.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198830364?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 09:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198830364","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Innovent Biologics Falls 3.15% in Regular Trading, Pfizer Deal Regulatory Uncertainty Compounds Biotech Sector Selloff","media":"Market Focus","content":"<p><p>On June 2, Innovent Biologics fell 3.15% in regular trading to HK$77.35 per share, with trading volume of HK$174 million. The decline marks the second consecutive session of pullback following the stock's 11%-plus surge on May 29 when the company announced a landmark $10.5 billion global strategic collaboration with Pfizer.</p><p>The Pfizer deal covers 12 early-stage oncology programs, with Innovent receiving $650 million upfront and up to $9.85 billion in milestone payments. Notably, Innovent's disclosure that the transaction requires regulatory approval has sparked market concern, particularly amid ongoing speculation about potential tightening of biomedical technology out-licensing (BD) regulations under the COINS Act framework.</p><p>The broader biotech sector experienced significant selling pressure, with Akeso down 6.21%, 3SBio down 8.32%, BeiGene down 3.56%, SKB Bio down 7.72%, and Remegen down 5.04%, creating systemic drag on Innovent.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Innovent Biologics Falls 3.15% in Regular Trading, Pfizer Deal Regulatory Uncertainty Compounds Biotech Sector Selloff</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Innovent Biologics Falls 3.15% in Regular Trading, Pfizer Deal Regulatory Uncertainty Compounds Biotech Sector Selloff\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-02 09:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 2, Innovent Biologics fell 3.15% in regular trading to HK$77.35 per share, with trading volume of HK$174 million. The decline marks the second consecutive session of pullback following the stock's 11%-plus surge on May 29 when the company announced a landmark $10.5 billion global strategic collaboration with Pfizer.</p><p>The Pfizer deal covers 12 early-stage oncology programs, with Innovent receiving $650 million upfront and up to $9.85 billion in milestone payments. Notably, Innovent's disclosure that the transaction requires regulatory approval has sparked market concern, particularly amid ongoing speculation about potential tightening of biomedical technology out-licensing (BD) regulations under the COINS Act framework.</p><p>The broader biotech sector experienced significant selling pressure, with Akeso down 6.21%, 3SBio down 8.32%, BeiGene down 3.56%, SKB Bio down 7.72%, and Remegen down 5.04%, creating systemic drag on Innovent.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1198830364","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198830364","pubTimestamp":1780364653,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 2, Innovent Biologics fell 3.15% in regular trading to HK$77.35 per share, with trading volume of HK$174 million. The decline marks the second consecutive session of pullback following the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动向提示|信达生物常规交易跌3.15%辉瑞交易监管不确定性加剧生物科技板块抛售","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On June 2, Innovent Biologics fell 3.15% in regular trading to HK$77.35 per share, with trading volume of HK$174 million. The decline marks the second consecutive session of pullback following the stock's 11%-plus surge on May 29 when the company announced a landmark $10.5 billion global strategic collaboration with Pfizer.The Pfizer deal covers 12 early-stage oncology programs, with Innovent receiving $650 million upfront and up to $9.85 billion in milestone payments. Notably, Innovent's disclosure that the transaction requires regulatory approval has sparked market concern, particularly amid ongoing speculation about potential tightening of biomedical technology out-licensing (BD) regulations under the COINS Act framework.The broader biotech sector experienced significant selling pressure, with Akeso down 6.21%, 3SBio down 8.32%, BeiGene down 3.56%, SKB Bio down 7.72%, and Remegen down 5.04%, creating systemic drag on Innovent.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198830364","isCrawlerRequest":true}